AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
(The Yates Network) BIND Therapeutics clinical investigators presented Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2013 Category: Global & Universal Source Type: news

New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets Regulatory Green Light
Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK. Perjeta has been granted a licence by the European Medicines Agency (EMA), for patients with previously untreated advanced HER2-positive breast cancer in combination with the current gold standard-of-care, Herceptin and chemotherapy (docetaxel)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Pneumonitis in a Patient on Docetaxel and CyclophosphamidePneumonitis in a Patient on Docetaxel and Cyclophosphamide
What was the cause of this breast cancer patient's rapidly progressive dyspnea and non-productive cough? Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2013 Category: Pharmaceuticals Source Type: news

NICE issues Appraisal Consultation Document on pemetrexed for the maintenance treatment of non-small-cell lung cancer
Source: NICE Area: News NICE has issued new draft guidance not recommending pemetrexed (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin. NICE has already recommended pemetrexed as a first line treatment option for NSCLC and as a maintenance treatment option following platinum-based chemotherapy in combination with gemcitabine, paclitaxel or docetaxel. This appraisal is concerned with the extension to the marketing authorisation for pemetrexed as a maintenance treatment following pemetrexed and cisplatin.   The committee noted th...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Comparing Costs of New Drugs in Prostate CancerComparing Costs of New Drugs in Prostate Cancer
A simplified model analyzing cost and survival finds that generic docetaxel and abiraterone are better value than cabazitaxel and sipuleucel-T. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Horizon scanning: Updated survival data for phase II trial of bavituximab for second-line treatment of non-small cell lung cancer
Source: BioSpace Area: News Peregrine Pharmaceuticals, Inc. has reported updated survival data from its randomised, double-blind, placebo-controlled phase IIb trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in 121 patients with second-line stage IIIb or IV non-squamous, non-small cell lung cancer (NSCLC). See previous NELM report for study details.   The data indicate a median overall survival of 11.7 months in the bavituximab arm compared to 7.3 months in the control arm (hazard ratio=0.73; p value=0.217).  The results also demonstrated that bavituximab was well-tolerated with no ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news

RCT: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in head and neck cancer (PARADIGM- a phase 3 trial).
Source: Lancet Oncology Area: News PARADIGM is a multicentre open-label phase 3 study comparing the use of docetaxel, cisplatin, and fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with locally advanced head and neck cancer. One hundred and forty five patients were randomly assigned in a 1:1 ratio to receive either induction chemotherapy with three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or carboplatin, or concurrent chemoradiotherapy alone with two cycles of bolus cisplatin. The prim...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news

KRAS+ Lung Cancer Responds to Targeted TherapyKRAS+ Lung Cancer Responds to Targeted Therapy
Dr. H. Jack West reports on a small but promising study that showed increased survival in KRAS mutated lung cancer using selumetinib and docetaxel. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Sequential docetaxel improved OS, DFS
Oakman C. Ann Oncol. 2013;doi:10.1093/annonc/mds627. (Source: HemOncToday.com)
Source: HemOncToday.com - February 7, 2013 Category: Cancer & Oncology Source Type: news

Phase II study of trastuzumab emtansine versus trastuzumab plus docetaxel for metastatic breast cancer
Source: JCO Area: News According to the results of a randomised Phase II study reported early online in the Journal of Clinical Oncology, first-line treatment of HER2-positive metastatic breast cancer (MBC) with trastuzumab emtansine (T-DM1) was associated with an improved progression-free survival (PFS) compared with trastuzumab plus docetaxel.   The authors note that trastuzumab plus taxane-based chemotherapy has been shown to be associated with improved outcomes versus chemotherapy alone in the first-line treatment of HER2-positive MBC. However MBC will eventually progress in most patients and chemotherapy-ass...
Source: NeLM - News - February 5, 2013 Category: Drugs & Pharmacology Source Type: news

ASCO GI: Docetaxel for Advanced Esophagogastric Adenocarcinoma Improves Survival in Second-Line Setting
Adding the chemotherapy docetaxel to active symptom control in advanced esophagogastric adenocarcinoma improves survival of patients. These are the results of the phase III COUGAR-02 trial. (Source: Cancer Network)
Source: Cancer Network - January 25, 2013 Category: Cancer & Oncology Source Type: news

Second-Line Docetaxel Benefits Seen For Esophagogastric Cancers
SAN FRANCISCO (IMNG) - Results of a phase III trial support a common clinical practice - giving docetaxel as second-line chemotherapy to patients with advanced adenocarcinomas of the stomach or esophagus... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news

Second-Line Docetaxel Affirmed for Esophagogastric CancerSecond-Line Docetaxel Affirmed for Esophagogastric Cancer
Second-line docetaxel therapy improved survival and pain symptoms, and was not associated with any deterioration in quality of life. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Esophageal Ca Survival Jumps with Docetaxel
SAN FRANCISCO (MedPage Today) -- Second-line chemotherapy with docetaxel for esophagogastric cancer led to a greater than 40% improvement in survival compared with only symptomatic treatment, results of a British study showed. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 22, 2013 Category: Gastroenterology Source Type: news